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Abstracts / Biol Blood Marrow Transplant 20 (2014) S151eS164S156Acute Myeloid Leukemia (AML) not in remission at time of
HSCT carries a very poor prognosis. We previously reported
a single institution experience indicating signiﬁcant activity
for myeloablative clofarabine/busulfan conditioning
(CloBu4) in refractory hematologic malignancies, particularly
in AML (Blood. 2011 Oct 13; 118(15)). In an effort to better
establish efﬁcacy of HSCT with CloBu4 for AML not in
remission we initiated a multi-center phase II study with a
target accrual of 75 pts. Only pts with active AML deﬁned as
>5% myeloblasts on bone marrow examination within 14
days of registration were eligible. AML was required to be
refractory to two lines of intensive induction, one line of
induction following relapse (CR > 6 month), or untreated
relapse (CR < 6 months). Pts receiving previous HSCT were
excluded. Busulfanwas administered as a single daily dose of
3.2 mg/kg IV x 4d (days -5 to -2) targeting a plasma AUC of
4500-5500 mM.min/day and clofarabine as a single daily dose
of 40 mg/m2 IV x 5d (days -6 to -2). An 8/8 HLA matched
related or unrelated donor was required. GVHD prophylaxis
was per institutional preference, but included calcineurin
inhibitor together with either mycophenolate mofetil or
methotrexate. Twelve centers across US and Canada are
participating. At time of interim analysis there were 60 pts
with 56 evaluable for toxicity and response with additional
pt accrual expected at time of abstract submission. One pt
enrolled but withdrew before conditioning. Pts had median
age of 56 yrs (range: 3-65 yrs), received a median of 2 in-
ductions and had a median of 26% bone marrow blasts
(range: 5-94%) within 14 days of enrollment. Matched un-
related donors were utilized in 46% of pts. Pts engrafted at a
median of 13 days (range: 9-25) for neutrophils and 16 days
(range: 8-72) for platelets. The most frequent grade 3-4 non-
hematologic toxicities reported by day + 100 as related to
conditioning were infections (N¼6, 11%) and aGVHD (N¼4,
7%). Grade 5 non-hematologic toxicities possibly related to
conditioning include neutropenic enterocolitis (N¼1),
aGVHD (N¼1), pneumonia (N¼1), alveolar hemorrhage
(N¼1), ascites/veno-occlusive disease (N¼1), and metabolic
acidosis / sepsis (N¼1). Morphologic remissionwas observed
92% of pts with response assessment at day + 30 (N¼53). The
cumulative incidence of aGVHD grades II-IV by day + 100,
accounting for relapse and death as competing risks, was 37%
[95% CI: 24, 50]. Non-relapse mortality and relapse at one
year was 25% [95% CI: 11%, 38%] and 43% [95% CI: 27, 58],
respectively. The estimated one year OS and DFS are 39% [95%
CI: 24%, 64%] and 32% [95% CI: 20%, 52%], respectively. In
summary, preliminary analysis of a multi-center study of
CloBu4 conditioning in AML not in remission exhibits
impressive early responses with NRM and relapse incidence
similar to previous trials utilizing this regimen.221
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Disease relapse and graft-versus-host disease (GVHD) are the
major causes of treatment failure after allogeneic stem cell
transplantation (SCT). The DNA methyltransferase inhibitor
azacitidine (AZA) possesses signiﬁcant anti-tumor activity in
myelodysplasia and acute myeloid leukemia (AML). Recently
its administration post-transplant has been shown to both
induce a CD8+ T cell response to a broad range of tumor
antigens and augment reconstitution of T regulatory cells.
We therefore prospectively studied the impact of post-
transplant AZA on the outcome of patients allografted for
AML. 37 patients were transplanted using an alemtuzumab
based ﬂudarabine/melphalan conditioning regimen. 36 mg/
m2 of AZAwas administered for ﬁve consecutive days at four
weekly intervals until 12 months post-transplant. AZA was
commenced at a median of 54 days (range 40-194) post-
transplant and was well tolerated. 31 patients completed
three or more cycles. 16 patients relapsed at a median time of
8 months post-transplant. No patient developed chronic
extensive GVHD. AZA induced a CD8+ T cell response to tu-
mor-speciﬁc peptides in 16 of the 31 patients who received
more than three treatment cycles. No such response was
observed in matched controls who received no post-trans-
plant AZA. Induction of a CD8+ Tcell responsewas associated
with an increased one year overall survival of 81% versus 41%
in patients with no CD8+ T cell response (p¼ 0.02). An
increased number of T regulatory cells was detected in 16
patients compared with matched controls. In conclusion
administration of AZA post-transplant is associated with a
low incidence of GVHD and induces a CD8+ T cell response to
tumor antigens which correlates with a reduced risk of
relapse. These data demonstrate the ability of AZA to
improve the outcome of allogeneic SCT, potentially through
epigenetic manipulation of the alloreactive response, and
require validation in a randomised clinical trial.222
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Background: AML patients are frequently consolidated with
Allo-SCT in CR1. There is no consensus about the regimen
intensity (RIC versus ablative) in this setting.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S151eS164 S157Methods: We retrospectively analyzed the outcomes of all
AML patients in CR1 who underwent Allo-SCT with RIC
regimen (Flu-Bu2-hATG) at UMass since 2010.
Results: 18 patients (12 males; 6 females) with a median age
of 67.5 (range 24-83) years were identiﬁed. Twelve (66%) had
prior MDS or poor prognostic cytogenetics. Induction
chemotherapy consisted of High dose Ara-C (HIDAC)/
Anthracycline (n¼17) and Decitabine (n¼1). Five patients
required reinduction to achieve a CR. Fourteen (78%)
received post CR therapy: HIDAC (n¼5), HIDAC/Hypo-
methylating agent (n¼3) and Hypomethylating agent alone
(n¼6). Seven (39%) patients had inadequate recovery of
counts (CRi). Median time from diagnosis to SCT was 130.5
(range 33 -384) days. Median Hematopoietic (H) SCT co-
morbidity index (CI) was 2.5 range (1- 9). SCT donors were
sibling (n¼2) and unrelated (n¼16). Seventeen (94%) pa-
tients were 8/8 HLA match and one (6%) was 7/8 HLA match.
Stem cell source was peripheral blood (n¼17) and G-CSF
primed marrow (n¼1). RIC dosing was Bu (3.2 mg/kg day x
2), Flu (30mg/m2 x 6) and hATG (20mg/kg x 3). Graft versus
Host Disease (GvHD) prophylaxis was calcineurin inhibitor/
mycophenolate-mofetil (MMF) (n¼16) and Sirolimus/MMF
(n¼2).
Median CD34 cells infusedwere 5 x 10e6/kg range (2.5-6).
All patients engrafted with a median time to neutrophil
engraftment of 15 days (range 10-22) and a median time to
platelet engraftment of 15 days (range 0-21). Non relapse
mortality at 100 days was 5.9%. Cumulative incidence of
grade 2-4 acute GvHD was 39%. For patients alive beyond 6
months the cumulative incidence of chronic gvhd was 64%.
Kaplan Meier estimate of 2 year overall (OS) and progression
free survival (PFS) was 80.5 % (95% CI 50.6-93.3%) and 69.9 %
(95% CI 36.7-88.0%) The median follow-up for the survivors
was 509 (59-1288) days. No patient with HSC-CI < 5 died
while all 3 patients with HSCT-CI > 6 expired (p < .001).
Presence of chronic gvhd was associated with a better PFS
(100% versus 32.1%) (p< .02) and a tendency for better OS
(100% versus 57.1%) (p¼ .06) indicating a preservation of
graft versus leukemia effect with this regimen.
Conclusion: Flu-Bu2-hATG RIC regimen has low early mor-
tality and improved PFS and OS for AML patients undergoing
Allo-SCT in CR1. The regimen should be evaluated in a pro-
spective clinical trial.223
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Chicago, ILThe alkylator Busulfan (Bu) is used in conditioning regimens
for acute leukemia prior to allogeneic stem cell transplant.
Multiple DNA repair mechanisms including mismatch repair
and base excision repair have been implicated in resistance
to Bu. The enzyme PARP is central to base excision repair. We
hypothesized that treatment of acute leukemia cell lines
with both ABT888 (Veliparib), an inhibitor of PARP 1 and 2,
and Buwould lead to synergistic cell kill and that this effect is
maximal in mismatch repair deﬁcient cells.
Two mismatch repair proﬁcient cell lines (K562 and HL60)
and 2 mismatch repair deﬁcient cell lines (NB4 and REH)
were treated with ABT888 alone, Bu alone or a combination
of both. In single drug experiments, doses of drug treatment
ranged from 0-400mcg/ml. In combination experiments a
ﬁxed dose of ABT888 of 1.25mcg/ml was utilized with Bu
doses varying from 0-200mcg/ml. This dose of ABT888 was
chosen as it approximated to patient blood levels in clinical
trials. After 24 hours of treatment, cells were washed and
resuspended in fresh medium. Proliferation of cells was
measured by standard 3H-thymidine uptake assay at 48
hours. Sigmoidal dose response curves and GI50 values were
then calculated. In addition, cells were tested for apoptosis
by ﬂow cytometry using activated caspase 3 and annexin/ PI
staining at 24 and 48 hours after treatment.
All 4 cell lines were found to be resistant to single agent
ABT888. Despite mismatch repair deﬁciency in REH cells,
therapeutic doses of ABT888 did not cause signiﬁcant de-
creases in proliferation. The effect of ABT888 was, as ex-
pected, much less evident in the mismatch repair proﬁcient
K562 cells. These cells were also relatively resistant to single
agent Bu in vitro. The combination of Bu and ABT888 was
synergistic in all cell lines with GI50 (micromoles/ml) for Bu
decreasing from 67.8 to 45.7 in K562, from 23.3 to 8.0 in
HL60, from 46.6 to 36.1 in NB4 and from 34.4 to 17.0 in REH
cells. The Combination Index was <1 in all cell lines indi-
cating synergy. Dose Reduction Index, indicating the factor
by which the dose of Bu can be decreased to achieve the
same treatment effect size, ranged from 1.45 to 3.1. The
synergistic effect was greatest in the mismatch repair deﬁ-
cient cell line REH (Combination Index 0.53, Dose Reduction
Index 3.1). As expected the synergistic effect observed did
not correlate with increased apoptotic death of leukemic
cells.
To our knowledge, this is the ﬁrst study to show synergy of a
clinically available PARP inhibitor with Bu. We believe this
data warrants further study with the potential clinical
application of increasing the anti-leukemic effect of stem cell
transplantation conditioned with Bu containing preparative
regimens.224
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Introduction: Overall survival (OS) after a standard allogeneic
hematopoietic cell transplantation (alloHCT) for refractory
